NVAX - CIK 0001000694
NOVAVAX INC (NVAX) reported net income of $440.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | $440.30M | +334.8% |
| FY 2024 | -$187.50M | +65.6% |
| FY 2023 | -$545.06M | +17.2% |
| FY 2022 | -$657.94M | +62.3% |
| FY 2021 | -$1.74B | -316.9% |
| FY 2020 | -$418.26M | -215.2% |
| FY 2019 | -$132.69M | +28.2% |
| FY 2018 | -$184.75M | -0.5% |
| FY 2017 |
NOVAVAX INC (NVAX) reported net income of $440.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, NOVAVAX INC's net income grew from -$19.36M to $440.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$183.77M |
| +34.4% |
| FY 2016 | -$279.97M | -78.4% |
| FY 2015 | -$156.94M | -89.2% |
| FY 2014 | -$82.95M | -59.6% |
| FY 2013 | -$51.98M | -82.4% |
| FY 2012 | -$28.51M | -47.2% |
| FY 2011 | -$19.36M | - |